Proteins

Product Data Sheet

VEGFR-2 Protein, Human (745a.a, HEK293, Fc)

Cat. No.: HY-P70635

Synonyms: Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase

insert domain receptor; Protein-tyrosine kinase receptor flk-1; VEGFR2; VEGF R2

Human Species: Source: HEK293

Accession: P35968 (A20-E764)

Gene ID: 3791

Molecular Weight: 150-160 kDa

PROPERTIES

AA Sequence	ASVGLPSVSL DLPRLSIQKD ILTIKANTTL QITCRGQRDL DWLWPNNQSG SEQRVEVTEC SDGLFCKTLT IPKVIGNDTG AYKCFYRETD LASVIYVYVQ DYRSPFIASV SDQHGVVYIT ENKNKTVVIP CLGSISNLNV SLCARYPEKR FVPDGNRISW DSKKGFTIPS YMISYAGMVF CEAKINDESY QSIMYIVVVV GYRIYDVVLS PSHGIELSVG EKLVLNCTAR TELNVGIDFN WEYPSSKHQH KKLVNRDLKT QSGSEMKKFL STLTIDGVTR SDQGLYTCAA SSGLMTKKNS TFVRVHEKPF VAFGSGMESL VEATVGERVR IPAKYLGYPP PEIKWYKNGI PLESNHTIKA GHVLTIMEVS ERDTGNYTVI LTNPISKEKQ SHVVSLVVYV PPQIGEKSLI SPVDSYQYGT TQTLTCTVYA IPPPHHIHWY WQLEEECANE PSQAVSVTNP YPCEEWRSVE DFQGGNKIEV
Appearance	NLTWYKLGPQ PLPIHVGELP TPVCKNLDTL WKLNATMFSN STNDILIMEL KNASLQDQGD YVCLAQDRKT KKRHCVVRQL TVLERVAPTI TGNLENQTTS IGESIEVSCT ASGNPPPQIM WFKDNETLVE DSGIVLKDGN RNLTIRRVRK EDEGLYTCQA CSVLGCAKVE AFFIIEGAQE KTNLE Lyophilized powder.
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/μg, determined by LAL method.
Reconsititution	It is not recommended to reconstitute to a concentration less than 100 μ g/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Page 1 of 2

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

VEGFR-2 protein, a tyrosine-protein kinase, serves as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, playing a pivotal role in the intricate regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It actively promotes the proliferation, survival, migration, and differentiation of endothelial cells, while also influencing the reorganization of the actin cytoskeleton. Certain isoforms, lacking a transmembrane domain like isoform 2 and isoform 3, may function as decoy receptors, modulating VEGFA, VEGFC, and/or VEGFD signaling. Specifically, isoform 2 acts as a negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the availability of free VEGFA and/or VEGFC, preventing their binding to FLT4. VEGFR-2 modulates FLT1 and FLT4 signaling through heterodimer formation. Binding of vascular growth factors to isoform 1 triggers multiple signaling cascades, including the activation of PLCG1, resulting in the production of diacylglycerol and inositol 1,4,5-trisphosphate and the subsequent activation of protein kinase C. Additionally, VEGFR-2 mediates the activation of MAP kinase signaling pathways, AKT1 signaling pathway, and the phosphorylation of PIK3R1, contributing to the reorganization of the actin cytoskeleton and the activation of PTK2/FAK1. Its crucial role extends to facilitating VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. VEGFR-2's phosphorylation activity includes PLCG1, FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1, and SRC, highlighting its comprehensive involvement in modulating diverse cellular processes.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA